ArticleJournal of clinical research in pediatric endocrinology2026
Glucocorticoid Dose and Type are Associated with Depression Scores in Youth with Classical Congenital Adrenal Hyperplasia
Article in Journal of clinical research in pediatric endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives.The Journal of clinical endocrinology and metabolism · 2026Review
- Clinical burden of classic congenital adrenal hyperplasia and glucocorticoid-related complications: a claims analysis.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: Adults with classical congenital adrenal hyperplasia (CAH) exhibit a higher lifetime prevalence of depression, but little is known about onset or etiology of mood disorders in this population. We therefore aimed to assess depression in youth with CAH, compared to controls, using the Children’s Depression Inventory (CDI). Methods: Youth with classical CAH due to 21-hydroxylase deficiency and age- and sex-matched controls completed the CDI and had analyte and genetic testing. Results: A total of 31 patients with CAH and 36 controls were included. Youth with CAH exhibited CDI measures that differed significantly by glucocorticoid dose and type. For glucocorticoid dose, significant correlations were found between CDI total T-score (r=0.42, p<0.05), as well as multiple subscores. Dose also predicted total T-score (β=1.75), Emotional-Problems (β=1.41), Negative-Self-Esteem (β=1.91), Functional-Problems (β=1.90), Ineffectiveness (β=1.56), and Interpersonal-Problems (β=2.11) (all p<0.01). For glucocorticoid type [dexamethasone n=7, hydrocortisone (HC) n=24], scores were higher in patients treated with dexamethasone for total T-score [dexamethasone: 59 (53.5-72), HC: 50 (43.75-55.75)], Emotional-Problems [dexamethasone: 63 (51.0-67.0), HC: 45 (42.0-56.5)], and Negative-Self-Esteem [dexamethasone: 53 (50.0-73.5), HC: 44 (44.0-51.0)] (all p<0.05). Conclusion: Higher HC doses and use of dexamethasone were both found to be associated with higher CDI scores in children and adolescents with classical CAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.